Skornova Ingrid, Simurda Tomas, Stasko Jan, Horvath Denis, Zolkova Jana, Holly Pavol, Brunclikova Monika, Samos Matej, Bolek Tomas, Schnierer Martin, Slavik Ludek, Kubisz Peter
Clin Lab. 2021 Apr 1;67(4). doi: 10.7754/Clin.Lab.2020.200820.
Fibrinogen plays an important role in hemostasis. The normal concentration of fibrinogen in blood plasma is between 1.8 - 4.2 g/L. Decreased fibrinogen levels are observed in congenital afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, disseminated intravascular coagulation, fibrinolytic therapy, some more severe hepatic parenchymal disorders, and increased blood loss. Elevated fibrinogen levels occur in inflammatory diseases and neoplastic diseases, in pregnancy, and postoperative conditions. Functional fibrinogen measurement is also one of the basic coagulation screening tests. The fibrinogen antigen assay is used to distinguish between qualitative and quantitative fibrinogen disorders.
The aim of the study was the use of fibrinogen determination methods in differential diagnosis of hypofibrinogenemia and dysfibrinogenemia, statistical evaluation and determine the relationship of fibrinogen Clauss assay, prothrombin time (PT) derived fibrinogen assay, and fibrinogen antigen in the group of 60 patients with congenital fibrinogen disorders (n = 40 dysfibrinogenemia; n = 20 hypofibrinogenemia).
The results measured by the PT-derived fibrinogen assay were approximately four times higher compared to the fibrinogen Clauss assay in the group of patients with dysfibrinogenemia. In patients with hypofibrinogenemia, there is a correlation (r = 0.9016) between the fibrinogen Clauss assay and PT-derived fibrinogen assay with a statistical significance of p < 0.0001. Using a linear or quadratic interpolation function, we were able to determine the fibrinogen Clauss assay and the fibrinogen antigen assay before analysis.
The higher level of the PT-derived fibrinogen assay compared to the fibrinogen Clauss assay in the group of patients with dysfibrinogenemia may pose a greater risk to asymptomatic patients who require diagnosis and treatment in case of bleeding. The fibrinogen value using the PT-derived fibrinogen assay could erroneously give a normal level. The use of the interpolation function is important to estimate the value of fibrinogen activity and antigen before the analysis itself by the Clauss assay or analysis by the fibrinogen antigen assay.
纤维蛋白原在止血过程中起重要作用。血浆中纤维蛋白原的正常浓度在1.8 - 4.2 g/L之间。在先天性无纤维蛋白原血症、低纤维蛋白原血症、异常纤维蛋白原血症、弥散性血管内凝血、纤维蛋白溶解治疗、一些更严重的肝实质疾病以及失血增加时,会观察到纤维蛋白原水平降低。在炎症性疾病、肿瘤性疾病、妊娠及术后情况下,纤维蛋白原水平会升高。功能性纤维蛋白原检测也是基本的凝血筛查试验之一。纤维蛋白原抗原检测用于区分纤维蛋白原的定性和定量紊乱。
本研究的目的是在60例先天性纤维蛋白原疾病患者(n = 40例异常纤维蛋白原血症;n = 20例低纤维蛋白原血症)中,使用纤维蛋白原测定方法进行低纤维蛋白原血症和异常纤维蛋白原血症的鉴别诊断、统计评估,并确定纤维蛋白原Clauss检测法、凝血酶原时间(PT)衍生纤维蛋白原检测法和纤维蛋白原抗原之间的关系。
在异常纤维蛋白原血症患者组中,PT衍生纤维蛋白原检测法测得的结果比纤维蛋白原Clauss检测法高出约四倍。在低纤维蛋白原血症患者中,纤维蛋白原Clauss检测法与PT衍生纤维蛋白原检测法之间存在相关性(r = 0.9016),统计学显著性p < 0.0001。通过使用线性或二次插值函数,我们能够在分析前确定纤维蛋白原Clauss检测法和纤维蛋白原抗原检测法。
在异常纤维蛋白原血症患者组中,PT衍生纤维蛋白原检测法的水平高于纤维蛋白原Clauss检测法,这可能会给那些在出血时需要诊断和治疗的无症状患者带来更大风险。使用PT衍生纤维蛋白原检测法得出的纤维蛋白原值可能会错误地显示为正常水平。在通过Clauss检测法进行分析或通过纤维蛋白原抗原检测法进行分析之前,使用插值函数来估计纤维蛋白原活性和抗原的值很重要。